RecruitingPhase 1NCT07053917

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability


Sponsor

Johns Hopkins University

Enrollment

20 participants

Start Date

Feb 9, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Psilocybin (Usona Institute) for people with hemiparesis after stroke, hemiplegia following ischemic stroke, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPsilocybin (Usona Institute)

Participants will receive psilocybin to test its safety. Secondary outcomes will assess recovery from post-stroke deficits.


Locations(1)

Johns Hopkins

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07053917


Related Trials